This study explored the safety and efficacy of a CXCR2 agonist and plerixafor for mobilization of HSCs for hematopoietic stem cell transplantation in patients with MM.
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...